JP2015533163A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015533163A5 JP2015533163A5 JP2015536853A JP2015536853A JP2015533163A5 JP 2015533163 A5 JP2015533163 A5 JP 2015533163A5 JP 2015536853 A JP2015536853 A JP 2015536853A JP 2015536853 A JP2015536853 A JP 2015536853A JP 2015533163 A5 JP2015533163 A5 JP 2015533163A5
- Authority
- JP
- Japan
- Prior art keywords
- multiple sclerosis
- laquinimod
- relapsing
- presenting
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 206010071068 Clinically isolated syndrome Diseases 0.000 claims 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims 1
- 229960004577 laquinimod Drugs 0.000 claims 1
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000000542 thalamic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713256P | 2012-10-12 | 2012-10-12 | |
| US61/713,256 | 2012-10-12 | ||
| PCT/US2013/064061 WO2014058979A2 (en) | 2012-10-12 | 2013-10-09 | Laquinimod for reducing thalamic damage in multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015533163A JP2015533163A (ja) | 2015-11-19 |
| JP2015533163A5 true JP2015533163A5 (https=) | 2016-11-24 |
Family
ID=50475887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015536853A Pending JP2015533163A (ja) | 2012-10-12 | 2013-10-09 | 多発性硬化症における視床損傷を低減するためのラキニモド |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140107154A1 (https=) |
| EP (1) | EP2961406A4 (https=) |
| JP (1) | JP2015533163A (https=) |
| KR (1) | KR20150080509A (https=) |
| CN (1) | CN105263325A (https=) |
| AR (1) | AR092993A1 (https=) |
| AU (2) | AU2013329348A1 (https=) |
| BR (1) | BR112015007782A2 (https=) |
| CA (1) | CA2884272A1 (https=) |
| CL (2) | CL2015000732A1 (https=) |
| EA (1) | EA201590726A1 (https=) |
| HK (1) | HK1218865A1 (https=) |
| IL (1) | IL237745A0 (https=) |
| MX (1) | MX2015004564A (https=) |
| PE (1) | PE20151435A1 (https=) |
| SG (1) | SG11201501874TA (https=) |
| TW (1) | TW201420101A (https=) |
| WO (1) | WO2014058979A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| HK1198296A1 (en) | 2012-02-16 | 2015-03-27 | Teva Pharmaceutical Industries Ltd. | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| EA201591507A1 (ru) * | 2013-02-15 | 2015-12-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение рассеянного склероза лахинимодом |
| TW201609098A (zh) * | 2013-12-20 | 2016-03-16 | 泰瓦藥品工業有限公司 | 拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於延緩亨丁頓舞蹈症進展的用途 |
| EA201692180A1 (ru) | 2014-04-29 | 2017-08-31 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| SG10202102198RA (en) * | 2016-09-13 | 2021-04-29 | Intekrin Therapeutics Inc | Treatment of multiple sclerosis with chs-131 |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
| CN113397757A (zh) * | 2021-06-07 | 2021-09-17 | 温州医科大学 | 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008527002A (ja) * | 2005-01-13 | 2008-07-24 | サートリス ファーマシューティカルズ， インコーポレイテッド | 神経変性障害および血液凝固障害を予防および処置するための新規組成物 |
| WO2008009407A2 (en) * | 2006-07-17 | 2008-01-24 | Novartis Ag | Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators |
| TW201014605A (en) * | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| RS54328B1 (sr) * | 2009-06-19 | 2016-02-29 | Teva Pharmaceutical Industries Ltd. | Tretman multiple skleroze lakvinimodom |
| PT2467372T (pt) * | 2009-08-10 | 2016-08-23 | Teva Pharma | Tratamento de distúrbios relacionados com bdnf usando laquinimod |
| WO2011086470A1 (en) * | 2010-01-13 | 2011-07-21 | Ramot At Tel-Aviv University Ltd | Treatment of multiple sclerosis |
| WO2012078591A1 (en) * | 2010-12-07 | 2012-06-14 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
| EP2691393B1 (en) * | 2011-03-31 | 2016-09-14 | Pfizer Inc | Novel bicyclic pyridinones |
| CN106344576A (zh) * | 2011-10-12 | 2017-01-25 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
| TW201804997A (zh) * | 2012-05-02 | 2018-02-16 | 以色列商泰瓦藥品工業有限公司 | 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途 |
-
2013
- 2013-10-09 US US14/049,411 patent/US20140107154A1/en not_active Abandoned
- 2013-10-09 CN CN201380053184.1A patent/CN105263325A/zh active Pending
- 2013-10-09 EA EA201590726A patent/EA201590726A1/ru unknown
- 2013-10-09 MX MX2015004564A patent/MX2015004564A/es unknown
- 2013-10-09 HK HK16106893.7A patent/HK1218865A1/zh unknown
- 2013-10-09 SG SG11201501874TA patent/SG11201501874TA/en unknown
- 2013-10-09 CA CA2884272A patent/CA2884272A1/en not_active Abandoned
- 2013-10-09 BR BR112015007782A patent/BR112015007782A2/pt active Search and Examination
- 2013-10-09 KR KR1020157012465A patent/KR20150080509A/ko not_active Withdrawn
- 2013-10-09 PE PE2015000472A patent/PE20151435A1/es not_active Application Discontinuation
- 2013-10-09 WO PCT/US2013/064061 patent/WO2014058979A2/en not_active Ceased
- 2013-10-09 AU AU2013329348A patent/AU2013329348A1/en not_active Abandoned
- 2013-10-09 JP JP2015536853A patent/JP2015533163A/ja active Pending
- 2013-10-09 EP EP13895446.6A patent/EP2961406A4/en not_active Withdrawn
- 2013-10-11 AR ARP130103705A patent/AR092993A1/es unknown
- 2013-10-11 TW TW102136847A patent/TW201420101A/zh unknown
-
2015
- 2015-03-15 IL IL237745A patent/IL237745A0/en unknown
- 2015-03-23 CL CL2015000732A patent/CL2015000732A1/es unknown
-
2016
- 2016-06-17 US US15/186,163 patent/US20160296511A1/en not_active Abandoned
- 2016-11-11 CL CL2016002873A patent/CL2016002873A1/es unknown
-
2017
- 2017-06-08 AU AU2017203896A patent/AU2017203896A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015533163A5 (https=) | ||
| CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
| JP2013520167A5 (https=) | ||
| MX2015004565A (es) | Metodo y dispositivo para conmutacion de camaras. | |
| JP2014507446A5 (https=) | ||
| JP2015525757A5 (https=) | ||
| CL2013001602A1 (es) | Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple. | |
| JP2014530840A5 (https=) | ||
| JP2015528502A5 (https=) | ||
| CL2014000844A1 (es) | Formulacion farmaceutica oral de liberacion prolongada en forma de multiparticulas, que comprende a) 40-o-(2-hidroxi)etil-rapamicina y b) al menos un recubrimiento de liberacion prolongada. | |
| JP2017514871A5 (https=) | ||
| JP2015534562A5 (https=) | ||
| WO2014058979A8 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| WO2013003669A3 (en) | Compositions, methods of use, and methods of treatment | |
| JP2016500312A5 (https=) | ||
| BR112012003280A2 (pt) | composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto. | |
| MX374944B (es) | Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria. | |
| JP2014526468A5 (https=) | ||
| JP2016540030A5 (https=) | ||
| WO2014153495A9 (en) | Novel stat3 inhibitors | |
| HUE041883T2 (hu) | Samidorphan (ALKS 33) és buprenorfin kombináció, depressziós zavarok kezelésére | |
| HUE046924T2 (hu) | Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra | |
| EP2987786A4 (en) | AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE | |
| JP2013231052A5 (https=) | ||
| JP2013523758A5 (https=) |